Last update Dec. 4, 2020



Safe substance and/or breastfeeding is the best option.

Used in the treatment and prophylaxis of influenza A and B.
Administered via inhalation or intravenously in two daily doses.

The low plasma concentrations reached make it unlikely that significant amounts will transfer into breastmilk (Tanaka 2009).

Its very low oral absorption, 2% (Cass 1999), prevents transfer into infant plasma from breastmilk (Skalli 2010, Tanaka 2009).

Its use is authorized in infants from 6 months of age.

Various medical associations and expert consensus consider its use to be safe during breastfeeding (Skalli 2010, Chen 2010, Tanaka 2009, ABM 2009, AEM 2009).

See below the information of this related product:


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Zanamivir in other languages or writings:


Zanamivir belongs to this group or family:


Main tradenames from several countries containing Zanamivir in its composition:


Variable Value Unit
Oral Bioavail. oral: 2 ; inhal: 17 %
Molecular weight 332 daltons
Protein Binding < 10 %
pKa 3.25 -
Tmax 1 - 2 hours
2.5 - 5.1 hours
Theoretical Dose < 0.015 (probable) mg/Kg/d
Relative Dose < 4.5 (probable) %
Ped.Relat.Dose < 0.8 (probable) %


  1. Skalli S, Ferreira E, Bussières JF, Allenet B. Grippe A/H1N1v 2009, grossesse et allaitement: quel antiviral choisir? [Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?]. Ann Pharm Fr. 2010 Abstract
  2. Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Breastfeeding travelers: precautions and recommendations. J Travel Med. 2010 Jan-Feb;17(1):32-47. Abstract Full text (link to original source) Full text (in our servers)
  3. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ. 2009 Abstract Full text (link to original source) Full text (in our servers)
  4. Agencia Española del Medicamento Uso de Oseltamivir y Zanamivir en niños de cualquier edad, en mujeres gestantes y mujeres en periodo de lactancia y en personas con problemas de deglución. \ Nota Informativa 2009 Full text (in our servers)
  5. PDR Zanamivir Drug Summary 2009 Full text (in our servers)
  6. Academy of Breastfeeding Medicine. Breastfeeding / Swine Flu Recommendations for Physicians from the Academy of Breastfeeding Medicine For immediate release (ABM) 2009 Full text (in our servers)
  7. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM